Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

When Peters first noticed blood on toilet paper after bowel movements at age 33, her doctors quickly dismissed it as a ...

A new clinical trial shows the immunotherapy drug dostarlimab may eliminate the need for surgery and chemotherapy in certain ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, ...

The numbers for bowel cancer, the third-most-common type worldwide, are rising particularly fast (see chart). Compared with ...

Investigators assessed whether a reported survival disadvantage in men with secondary rectal cancer following prostate cancer radiation therapy vs primary rectal cancer is due to patient ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.